Article

Glaucoma 360: Getting updated with Glauconix Biosciences

 

Glauconix Biosciences' Kimberly Southern (CEO) and Karen Torrejon, PhD (CSO) sit down with Ophthalmology Times'® Sheryl Stevenson to discuss the company's role in using innovative platform technology to reduce the cost of ophthalmic drug development as well as what models are in their 2020 pipeline for the glaucoma and other eye-related diseases space, during this year's Glaucoma 360 annual meeting in San Francisco, California.

See more Glaucoma 360 content here. 

 

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.